In8Bio (INAB) Amortizatization of Intangibles (2021 - 2026)
In8Bio (INAB) posted Amortizatization of Intangibles of $108000.0 for Q1 2026, down 9.24% sequentially from $119000.0 in Q4 2025, and down 55.0% YoY from $240000.0 in Q1 2025.
In8Bio (INAB) Amortizatization of Intangibles (2021 - 2026) Analysis & Trends
In8Bio has reported Amortizatization of Intangibles for 6 years, with the latest figure at $108000.0 in Q1 2026.
- Quarterly Amortizatization of Intangibles fell 55.0% year-over-year to $108000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $639000.0 (down 28.6% YoY) and the FY2025 annual result came in at $771000.0, down 10.24% from the prior year.
- Amortizatization of Intangibles declined to $108000.0 in Q1 2026 per INAB's latest filing, from $119000.0 in the prior quarter.
- Over five years, Amortizatization of Intangibles peaked at $286000.0 in Q2 2025 and troughed at $90000.0 in Q3 2022.
- A 5-year average of $180588.2 and a median of $193000.0 in 2024 frame the typical range for Amortizatization of Intangibles.
- The sharpest annual moves came in 2023 and 2026: Amortizatization of Intangibles soared 164.44% in 2023, then tumbled 55.0% in 2026.
- Over 5 years, Amortizatization of Intangibles stood at $120000.0 in 2022, then soared by 79.17% to $215000.0 in 2023, then advanced by 8.84% to $234000.0 in 2024, then plunged by 49.15% to $119000.0 in 2025, then slipped by 9.24% to $108000.0 in 2026.
- According to Business Quant data, Amortizatization of Intangibles over the past three periods registered $108000.0, $119000.0, and $126000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 678,000.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | In8Bio | 24.34 Mn | 24.34 Mn | - | 140,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 62,000.00 |
| Jun 30, 2026 | 62,000.00 |
| Mar 31, 2026 | 108,000.00 |
| Mar 31, 2026 | 108,000.00 |
| Dec 31, 2025 | 119,000.00 |
| Dec 31, 2025 | 119,000.00 |
| Sep 30, 2025 | 126,000.00 |
| Sep 30, 2025 | 126,000.00 |
| Jun 30, 2025 | 286,000.00 |
| Jun 30, 2025 | 286,000.00 |
| Mar 31, 2025 | 240,000.00 |
| Mar 31, 2025 | 240,000.00 |
| Dec 31, 2024 | 234,000.00 |
| Dec 31, 2024 | 234,000.00 |
| Sep 30, 2024 | 228,000.00 |
| Sep 30, 2024 | 228,000.00 |
| Jun 30, 2024 | 193,000.00 |
| Jun 30, 2024 | 193,000.00 |
| Mar 31, 2024 | 204,000.00 |
| Mar 31, 2024 | 204,000.00 |